The investigational medicinal product should generally be taken from a batch whose size is at least 1/10 of the largest production batch (if several production batch sizes exist) or 100 000 units, whichever is greater, unless otherwise justified by the applicant.
If the production batch size is less than 100000 units, a full production batch must be used for the bioequivalence study.